Probiotics have been proposed as a prevention or treatment for pediatric overweight and obesity.
Objective:
Conduct a scoping review on probiotic use in children and adolescents with overweight or obesity and those with weight-related conditions and to identify knowledge gaps and research priorities.
Data Sources:
Seven databases using keywords and medical subject heading terms for articles reporting probiotic use in children or adolescents with overweight or obesity published from database conception until initiation of the study.
Study Selection:
Articles reporting primary data on probiotics use in children or adolescents with overweight or obesity.
Data Extraction:
We utilized the Arksey and O'Malley framework, PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines, followed a predetermined study protocol for level-one abstract and level-two full-text screenings, synthesized information into subject-area domains, and identified research gaps.
Limitations:
Heterogeneity of probiotic interventions, host factors, and genomics.
Results:
Database search yielded 1356 unique articles with 19 randomized placebo-controlled studies, 945 participants, duration of interventions from 8 weeks to 9 months. Disease indications included Nonalcoholic Fatty Liver Disease, insulin resistance, hypercholesterolemia, Prader–Willi Syndrome, metabolic syndrome, and obesity. Limited and heterogeneous evidence for probiotic use in children and adolescents with weight-related conditions noted. Heterogeneity among published articles in probiotic strains, doses, design, biomarkers, confirmation, and outcomes observed.
Conclusions:
Despite complex existing and limited data, studies to date of children and adolescents with overweight and obesity demonstrate potential beneficial treatment effects of probiotics on BMI, adiposity, metabolic parameters, inflammatory markers, fatty liver, transaminase levels, and glucose metabolism. Clinical trials to address heterogeneous results are needed.
Get full access to this article
View all access options for this article.
References
1.
KumarS, KellyAS. Review of childhood obesity: From epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo Clin Proc, 2017; 92:251–265.
2.
GoldinBR, GorbachSL. Clinical indications for probiotics: An overview. Clin Infect Dis, 2008; 46(SUPPL. 2 PG-S96-S100):S96–S100.
3.
BenningaMA, VinkM, AkkermansLMA, et al.Intestinal Microbiota and Its Role in the Development of Paediatric Gastrointestinal Disorders. The Netherlands: Wageningen Academic Publishers, 2017.
4.
MazzolaG, AloisioI, Di GioiaD, et al.Infant Development, Currently the Main Applications of Probiotics and Prebiotics?. Poole, United Kingdom: Caister Academic, 2015.
5.
CaniPD, DelzenneNM. Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care, 2007; 10:729–734.
6.
MaX, HuaJ, LiZ. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol, 2008; 49:821–830.
7.
YinYN, YuQF, FuN, et al.Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World J Gastroenterol, 2010; 16:3394–3401.
8.
Moya-PérezA, NeefA, SanzY. Bifidobacterium pseudocatenulatum CECT 7765 reduces obesity-associated inflammation by restoring the lymphocyte-macrophage balance and gut microbiota structure in high-fat diet-fed mice. PLoS One, 2015; 10:e0126976.
9.
BlautM, BischoffSC. Probiotics and obesity. Ann Nutr Metab, 2010; 57Suppl:20–23.
10.
KalliomäkiM, ColladoMC, SalminenS, IsolauriE. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr, 2008; 87:534–538.
11.
MillionM, MaraninchiM, HenryM, et al.Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int J Obes (Lond), 2012; 36:817–825.
12.
SchwiertzA, JacobiM, FrickJ-S, et al.Microbiota in pediatric inflammatory bowel disease. J Pediatr, 2010; 157:240–244.e1.
13.
ColladoMC, DonatE, Ribes-KoninckxC, et al.Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease. BMC Microbiol, 2008; 8:232.
14.
ColquhounHL, LevacD, O'BrienKK, et al.Scoping reviews: Time for clarity in definition, methods, and reporting. J Clin Epidemiol, 2014; 67:1291–1294.
15.
PhamMT, RajićA, GreigJD, SargeantJM, PapadopoulosA, McewenSA. A scoping review of scoping reviews: Advancing the approach and enhancing the consistency. Res Synth Methods, 2014; 5:371–385.
16.
NyanchokaL, Tudur-SmithC, ThuVN, et al.A scoping review describes methods used to identify, prioritize and display gaps in health research. J Clin Epidemiol, 2019; 109:99–110.
17.
ArkseyH, O'MalleyL. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol Theory Pract, 2005; 8:19–32.
18.
TriccoAC, LillieE, ZarinW, et al.PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med, 2018; 169:467–473.
19.
McHughML. Lessons in biostatistics interrater reliability: The kappa statistic. Biochem Med, 2012; 22:276–282.
20.
VidehultFK, AnderssonY, OhlundI, et al.Impact of probiotics during weaning on the metabolic and inflammatory profile: Follow-up at school age. Int J Food Sci Nutr, 2015; 66(6 PG-686-691):686–691.
21.
GøbelRJ, LarsenN, JakobsenM, et al.Probiotics to adolescents with obesity: Effects on inflammation and metabolic syndrome. J Pediatr Gastroenterol Nutr, 2012; 55:673–678.
22.
JonesRB, AldereteTL, MartinAA, et al.Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: A 16-week, randomized, placebo-controlled trial. Pediatr Obes, 2018; 13(11 PG-705-714):705–714.
23.
MiccheliA, CapuaniG, MariniF, et al.Urinary 1 H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. Int J Obes, 2015; 39(7 PG-1118-1125):1118–1125.
24.
ChenR, AiZ, YangX, et al.Effect of probiotics intake on obese children. Horm Res Paediatr, 2019; 91(PG-222-223):222–223.
25.
GombertM, Sanchis ChordaJ, Gomez Del PulgarE, et al.Improvement of chronic inflammation in obese children consecutive to probiotic intake. Obes Facts, 2019; 12(PG-119):119.
26.
AlisiA, BedogniG, BavieraG, et al.Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2014; 39:1276–1285.
27.
GoyalP, ThapaBR, SharmaNR, BhatiaA. Probiotic and lifestyle modification in obese pediatrics with non-alcoholic fatty liver disease. Indian J Community Heal, 2019; 31(1 SE-Original Article):50–56.
28.
SafaviM, FarajianS, KelishadiR, et al.The effects of synbiotic supplementation on some cardio-metabolic risk factors in overweight and obese children: A randomized triple-masked controlled trial. Int J Food Sci Nutr, 2013; 64:687–693.
29.
HerreraL, StrongD, KnightR, RheeK. Effect of probiotics and dietary changes on inflammatory markers and adiposity in children. Gastroenterology, 2018; 154(6 PG-S-200):S-200.
30.
Ramon-KrauelM, Amat-BouM, García-RiveraS, et al.Effects of Bifidobacterium animalis subsp. lactis on children with Prader-Willi syndrome: A randomized, double-blind, placebo-controlled, crossover trial. Horm Res Paediatr, 2019; 91(PG-67-68):67–68.
31.
Amat-BouM, Garcia-RiberaS, ClimentE, et al.Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial. Nutrients, 2020; 12:3123.
32.
FamouriF, ShariatZ, HashemipourM, et al.Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr, 2017; 64:413–417.
33.
KianifarHR, AhanchianH, SafarianM, et al.Effects of synbiotics on anthropometric indices of obesity in children: A randomized double-blind placebo-controlled pilot study. Top Clin Nutr, 2018; 33:118–126.
34.
KelishadiR, FarajianS, SafaviM, et al.A randomized triple-masked controlled trial on the effects of synbiotics on inflammation markers in overweight children. J Pediatr (Rio J), 2014; 90:161–168.
35.
PassarielloA, MalamisuraM, LeoneL, et al.Positive effect of a new symbiotic formulation containing lactobacillus paracasei B21060 in children with familial hypercholesterolemia. J Clin Gastroenterol, 2016; 50:S218–S219.
36.
GaoX, ZhuY, WenY, et al.Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatol Res, 2016; 46:1226–1233.
37.
SansottaN, PeroniDG, RomanoS, et al.The good bugs: The use of probiotics in pediatrics. Curr Opin Pediatr, 2019; 31(5 PG-661-669):661–669.
38.
SharptonSR, MarajB, Harding-TheobaldE, et al.Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression. Am J Clin Nutr, 2019; 110(1 PG-139-149):139–149.
39.
XiaoMW, LinSX, ShenZH, et al.Systematic review with meta-analysis: The effects of probiotics in nonalcoholic fatty liver disease. Gastroenterol Res Pract, 2019; 2019(PG-):1484598.
40.
VajroP, MandatoC, LicenziatiMR, et al.Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr, 2011; 52:740–743.
41.
NobiliV, SanyalAJ. Treatment of nonalcoholic fatty liver disease in adults and children: A closer look at the arsenal. J Gastroenterol, 2012; 47(1 PG-29-36):29–36.
42.
KumarS, KingEC, ChristisonAL, et al.Health outcomes of youth in clinical pediatric weight management programs in POWER. J Pediatr, 2019; 208:57–65.e4.
43.
LarsenN, VogensenFK, GøbelRJ, et al.Effect of Lactobacillus salivarius Ls-33 on fecal microbiota in obese adolescents. Clin Nutr, 2013; 32(6 PG-935-940):935–940.
44.
IsolauriE, SalminenS. The impact of early gut microbiota modulation on the risk of child disease: Alert to accuracy in probiotic studies. Benef Microbes, 2015; 6(2 PG-167-171):167–171.
45.
MussoG, GambinoR, CassaderM. Obesity, diabetes, and gut microbiota: The hygiene hypothesis expanded?. Diabetes Care, 2010; 33(10 PG-2277-2284):2277–2284.
46.
AmarJ, BurcelinR, RuidavetsJB, et al.Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr, 2008; 87:1219–1223.
47.
DeopurkarR, GhanimH, FriedmanJ, et al.Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care, 2010; 33:991–997.
48.
GhanimH, SiaCL, UpadhyayM, et al.Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am J Clin Nutr, 2010; 91:940–949.
49.
PalmerC, BikEM, DiGiulioDB, et al.Development of the human infant intestinal microbiota. PLoS Biol, 2007; 5:e177.
50.
PendersJ, ThijsC, VinkC, et al.Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics, 2006; 118:511 LP–521.
51.
PendersJ, VinkC, DriessenC, et al.Quantification of Bifidobacterium spp., Escherichia coli and Clostridium difficile in faecal samples of breast-fed and formula-fed infants by real-time PCR. FEMS Microbiol Lett, 2005; 243:141–147.
52.
NilssonAC, OstmanEM, HolstJJ, BjörckIME. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. J Nutr, 2008; 138:732–739.
53.
LuotoR, KalliomäkiM, LaitinenK, IsolauriE. The impact of perinatal probiotic intervention on the development of overweight and obesity: Follow-up study from birth to 10 years. Int J Obes (Lond), 2010; 34:1531–1537.
54.
CrawfordPA, CrowleyJR, SambandamN, et al.Regulation of myocardial ketone body metabolism by the gut microbiota during nutrient deprivation. Proc Natl Acad Sci U S A, 2009; 106:11276–11281.
